المؤلفون: Satoshi Yamasaki, Hiroatsu Iida, Akio Saito, Morio Matsumoto, Yoshiaki Kuroda, Tohru Izumi, Akiko M. Saito, Hiroaki Miyoshi, Koichi Ohshima, Hirokazu Nagai, Hiromi Iwasaki

المصدر: Hematology Reports, Vol 16, Iss 2, Pp 336-346 (2024)

مصطلحات موضوعية: peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, transplant-ineligible, older, gemcitabine, cisplatin, Diseases of the blood and blood-forming organs, RC633-647.5

الوصف: Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains controversial. The objective of this study was to characterize the safety and efficacy of romidepsin as consolidation therapy after gemcitabine, dexamethasone, and cisplatin (GDP) therapy (GDPR). This study of patients treated between March 2019 and March 2021 was registered with the Japan Registry of Clinical Trials (registration number: jRCT0000000519). If complete response, partial response, or stable disease was confirmed after 2–4 GDP cycles, romidepsin was administered every 4 weeks for 1 year. Seven patients with relapsed/refractory (R/R) PTCL (T-follicular helper phenotype [n = 1] and angioimmunoblastic T-cell lymphoma [n = 6]) were included in this prospective study (PTCL-GDPR). After a median follow-up of 34 months of patients in PTCL-GDPR, the 2-year overall survival rate was 71%, and the overall response rate after treatment was 57%. Common adverse events in patients with PTCL-GDPR included hematological toxicities such as neutropenia, which improved with supportive treatment. There were no treatment-related mortalities. GDPR might be safe and effective in elderly transplant-ineligible patients with R/R PTCL; however, further investigation is required.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2038-8330/16/2/34Test; https://doaj.org/toc/2038-8330Test

الوصول الحر: https://doaj.org/article/5dc4c27699d24b06ab94ab4efa6a4af8Test

المؤلفون: Ken Tanaka, Hiroaki Miyoshi, Yusuke Yamashita, Ryuta Iwamoto, Yuma Yokoya, Yuichi Tochino, Fumiko Arakawa, Shinobu Tamura, Shin-Ichi Murata, Takashi Sonoki, Koichi Ohshima

المصدر: Hematology Reports, Vol 15, Iss 4, Pp 662-669 (2023)

مصطلحات موضوعية: classic hodgkin lymphoma, lymphocyte rich classic hodgkin lymphoma, angioimmunoblastic T-cell lymphoma, secondary non-hodgkin lymphoma, Diseases of the blood and blood-forming organs, RC633-647.5

الوصف: We report a case of a 24-year-old man who developed angioimmunoblastic T-cell lymphoma (AITL) after treatment for refractory lymphocyte-rich classic Hodgkin lymphoma (LR-CHL). This patient was treated with the BV+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) protocol for LR-CHL but progressed before completing chemotherapy. The pathological imaging showed the typical findings of LR-CHL at the first onset and first progression. Rescue chemotherapy and high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (AHSCT) were performed for refractory LR-CHL, and complete remission was achieved. However, the recurrence was suspected 6 months after AHSCT. The pathological findings of the lymph node biopsy at this time were different from those of the previous two lymph node biopsies, demonstrating findings of AITL. The finding of the immunohistochemical staining and polymerase chain reaction results supported the diagnosis. Although it has been reported that the risk for the development of non-Hodgkin lymphoma after treatment for Hodgkin lymphoma is increased, most are B-cell lymphomas, and few cases of AITL have been reported. AITL is a type of peripheral T-cell lymphoma that generally occurs in middle-aged and elderly people and that rarely occurs in young people. Here, we were able to make an accurate diagnosis by performing re-examination even when recurrence of LR-CHL was suspected. As there are no detailed case reports of AITL developing into secondary non-Hodgkin lymphoma, here we report on an identified case.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2038-8330/15/4/67Test; https://doaj.org/toc/2038-8330Test

الوصول الحر: https://doaj.org/article/4012cc9982094fbcac92fe7a8036bffeTest

المؤلفون: Reiji Muto, Hiroaki Miyoshi, Kazutaka Nakashima, Mai Takeuchi, Makoto Hamasaki, Koichi Ohshima

المصدر: Cancer Medicine, Vol 13, Iss 6, Pp n/a-n/a (2024)

مصطلحات موضوعية: adult T‐cell leukemia/lymphoma, malignant lymphoma, T‐cell lymphoma, T‐follicular helper phenotype, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Aims T‐follicular helper (TFH) cells are effector T‐cells that are crucial for B‐cell selection and differentiation. T‐cell lymphomas derived from TFH cells have distinct characteristics. Additionally, in the World Health Organization (WHO) classification 5th edition, three lymphomas were introduced as independent disease entities with TFH cell origin. We aimed to investigate the clinicopathological features of adult T‐cell leukemia/lymphoma (ATLL) with a TFH phenotype (TFHP). Methods and Results We performed TFH immunohistochemistry analysis of five biomarkers for the biopsy specimen, with TFHP being indicated by a positive result for more than two markers. Among 75 cases of ATLL, 37.3% of them showed TFHP. Compared with cases of ATLL without TFHP, cases of ATLL with TFHP showed higher C‐reactive protein levels (p = 0.0219) and increased high endothelial venule proliferation (p = 0.024). However, there were no significant between‐group differences in overall survival as well as other clinical and morphological findings. Furthermore, there was no significant between‐group difference in TFH markers and FOXP3 expression. Conclusion Some patients with ATLL may present a TFHP, which should not preclude the diagnosis of ATLL. Although presenting a TFHP does not affect prognosis, it is important to identify cases of ATLL with a TFHP since it may inform future treatment strategies.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-7634Test

الوصول الحر: https://doaj.org/article/229c9be895644da5b37014378a78e88cTest

المؤلفون: Yasumasa Shimasaki, Hiroaki Miyoshi, Keisuke Kawamoto, Noriaki Yoshida, Tatsuzo Mishina, Kazutaka Nakashima, Teppei Imamoto, Takeshi Sugio, Eriko Yanagida, Takeharu Kato, Kyohei Yamada, Mai Takeuchi, Takaharu Suzuki, Mayuko Moritsubo, Takuya Furuta, Yoshitaka Imaizumi, Jun Takizawa, Koji Kato, Junji Suzumiya, Ritsuro Suzuki, Koichi Ohshima

المصدر: Cancer Medicine, Vol 13, Iss 3, Pp n/a-n/a (2024)

مصطلحات موضوعية: pathology, peripheral T‐cell lymphoma not otherwise specified, PTCL‐GATA3, PTCL‐TBX21, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Aim Peripheral T‐cell lymphoma not otherwise specified (PTCL‐NOS) is a heterogeneous disease that can be classified into the PTCL‐TBX21 and PTCL‐GATA3 subtypes. Methods In this study, we compared the clinicopathological features of PTCL‐NOS in a Japanese cohort, classified using an IHC algorithm. Results One hundred patients with PTCL‐NOS were categorized as having PTCL‐TBX21 (n = 55), PTCL‐GATA3 (n = 24), or PTCL‐unclassified (n = 21). When comparing PTCL‐TBX21 and PTCL‐GATA3, PTCL‐TBX21 showed significantly lower CD4 positivity (p = 0.047), lower counts of high endothelial venules (p = 0.032), and a tendency for a better response to initial treatment (p = 0.088). Gene expression analysis using the nCounter system showed higher expression of tumor immunity‐related genes, such as PD‐L1, LAG3, and IDO1, in PTCL‐TBX21 than in PTCL‐GATA3. PTCL‐GATA3 had significantly worse overall survival (OS) than those with PTCL‐TBX21 (p = 0.047), although a similar tendency was observed for progression‐free survival (PFS) (p = 0.064). PTCL‐GATA3 was a prognostic factor for OS in univariate analysis (HR 2.02; 95% CI, 1.09–3.77; p = 0.027), although multivariate analysis did not show significance (HR 2.07; 95% CI, 0.93–4.61; p = 0.074). In the PFS analysis, PTCL‐GATA3 was an independent prognostic factor by univariate analysis (HR 1.96; 95% CI, 1.08–3.56; p = 0.027) and multivariate analysis (HR 2.34; 95% CI, 1.07–5.11; p = 0.032). Conclusion The classification of PTCL‐NOS into PTCL‐TBX21 and PTCL‐GATA3 is useful for predicting the prognosis of Japanese patients and stratifying the administration of tumor immune checkpoint inhibitors in clinical practice.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-7634Test

الوصول الحر: https://doaj.org/article/9754c08ddfa14711831af32841f71aacTest

المؤلفون: Airi Miki, Masaru Tani, Kenji Tsutsui, Teppei Wakita, Yuki Horibe, Yoichi Kakuta, Koichi Tsutahara, Jun Ishiko, Kyohei Yamada, Hiroaki Miyoshi, Koichi Ohshima, Tetsuya Takao

المصدر: IJU Case Reports, Vol 7, Iss 1, Pp 11-13 (2024)

مصطلحات موضوعية: RAPN, T‐cell lymphoma, Diseases of the genitourinary system. Urology, RC870-923

الوصف: Introduction Renal involvement by non‐Hodgkin's lymphoma is very rare, and the kidney as the primary site of this lymphoma is much more uncommon. We report a case of primary renal peripheral T‐cell lymphoma, not otherwise specified, treated with partial nephrectomy. Case presentation A 63‐year‐old man was hospitalized with coronavirus infectious disease, emerged in 2019 in the emergency department. Computed tomography examination showed a 2‐cm renal mass in the right kidney. Abdominal enhanced computed tomography examination revealed that the noted mass showed good enhancement in the corticomedullary phase and washout in the nephrogenic phase. No metastatic lesions were found. He was diagnosed as having cT1aN0M0 renal cell carcinoma, and robotic‐assisted partial nephrectomy was carried out. The pathological diagnosis was peripheral T‐cell lymphoma, not otherwise specified. He has been followed for 20 months after robotic‐assisted partial nephrectomy without additional treatment and recurrence. Conclusion We experienced a primary renal peripheral T‐cell lymphoma, not otherwise specified that was followed up without treatment after surgery.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2577-171XTest

الوصول الحر: https://doaj.org/article/fb7c017986e341a391db526612a24594Test

المؤلفون: Ayumi Nagayama, Hironori Kusano, Hiroyuki Kawano, Jun Akiba, Koichi Ohshima, Masahito Nakano, Osamu Nakashima, Ryoko Kuromatsu, Takumi Kawaguchi, Toru Nakamura, Toshi Abe, Tsutomu Kumabe, Yasuko Mizushima, Yoshiki Naitou, 中島 収, 中村 徹, 中野 聖士, 内藤 嘉紀, 大島 孝一, 安陪 等思, 川口 巧, 川野 祐幸, 水島 靖子, 秋葉 純, 草野 弘宣, 長山 亜由美, 隈部 力, 黒松 亮子

المصدر: 超音波検査技術 / Japanese Journal of Medical Ultrasound Technology. 2023, 48(4):398

المؤلفون: Ai Matsumoto, Ayaka Sakaki, Fumiko Arakawa, Hideki Kosako, Hiroki Hosoi, Ken Tanaka, Koichi Ohshima, Naoyuki Nakao, Ryuta Iwamoto, Shin-Ichi Murata, Shogo Murata, Takashi Sonoki, Toshikazu Yamoto, Toshiki Mushino

المصدر: Internal Medicine. 2023, 62(13):1977

المؤلفون: Atsujiro Nishioka, Hiroo Katsuya, Hiroshi Ureshino, Kazuharu Kamachi, Keita Kai, Keitaro Ishii, Koichi Ohshima, Mai Fujita, Mai Takeuchi, Mariko Yoshimura, Shinya Kimura, Sho Okamoto, Tatsuro Watanabe, Toshiaki Nagaie, Toshihiko Ando, Yasushi Kubota

المصدر: Internal Medicine. 2023, 62(9):1335

المؤلفون: Mai Takeuchi, Hiroaki Miyoshi, Yuichiro Semba, Kyohei Yamada, Kazutaka Nakashima, Kensaku Sato, Takuya Furuta, Mayuko Moritsubo, Yusuke Ogura, Ken Tanaka, Teppei Imamoto, Fumiko Arakawa, Kei Kohno, Koichi Ohshima

المصدر: Haematologica, Vol 108, Iss 12 (2023)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: https://haematologica.org/article/view/11153Test; https://doaj.org/toc/0390-6078Test; https://doaj.org/toc/1592-8721Test

الوصول الحر: https://doaj.org/article/474443e71aba4f1d80bedd92934284b7Test

المؤلفون: Noriaki Hashimoto, Hiroyuki Hanada, Hiroaki Miyoshi, Miharu Nagaishi, Kensaku Sato, Hidekata Hontani, Koichi Ohshima, Ichiro Takeuchi

المصدر: Journal of Pathology Informatics, Vol 15, Iss , Pp 100359- (2024)

مصطلحات موضوعية: Digital pathology, Mixture of experts, Multiple instance learning, Whole slide image, Flow cytometry, Computer applications to medicine. Medical informatics, R858-859.7, Pathology, RB1-214

الوصف: In this study, we present a deep-learning-based multimodal classification method for lymphoma diagnosis in digital pathology, which utilizes a whole slide image (WSI) as the primary image data and flow cytometry (FCM) data as auxiliary information. In pathological diagnosis of malignant lymphoma, FCM serves as valuable auxiliary information during the diagnosis process, offering useful insights into predicting the major class (superclass) of subtypes. By incorporating both images and FCM data into the classification process, we can develop a method that mimics the diagnostic process of pathologists, enhancing the explainability. In order to incorporate the hierarchical structure between superclasses and their subclasses, the proposed method utilizes a network structure that effectively combines the mixture of experts (MoE) and multiple instance learning (MIL) techniques, where MIL is widely recognized for its effectiveness in handling WSIs in digital pathology. The MoE network in the proposed method consists of a gating network for superclass classification and multiple expert networks for (sub)class classification, specialized for each superclass. To evaluate the effectiveness of our method, we conducted experiments involving a six-class classification task using 600 lymphoma cases. The proposed method achieved a classification accuracy of 72.3%, surpassing the 69.5% obtained through the straightforward combination of FCM and images, as well as the 70.2% achieved by the method using only images. Moreover, the combination of multiple weights in the MoE and MIL allows for the visualization of specific cellular and tumor regions, resulting in a highly explanatory model that cannot be attained with conventional methods. It is anticipated that by targeting a larger number of classes and increasing the number of expert networks, the proposed method could be effectively applied to the real problem of lymphoma diagnosis.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2153353923001736Test; https://doaj.org/toc/2153-3539Test

الوصول الحر: https://doaj.org/article/9d5f8550a204454c965758cbe4462f42Test